Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00700206 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT00700206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00700206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Lead sponsor
Telik
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
July 31, 2011
Enrollment
86 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)